rosiglitazone has been researched along with Disease Exacerbation in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 39 (54.93) | 29.6817 |
| 2010's | 29 (40.85) | 24.3611 |
| 2020's | 3 (4.23) | 2.80 |
| Authors | Studies |
|---|---|
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Chen, M; Chen, Q; Liu, Q; Min, Q; Yu, X; Zhang, S; Zhuang, L | 1 |
| Calvo, JC; Gantov, M; Lotufo, C; Pagnotta, P; Riera, MF; Rindone, GM; Toneatto, J | 1 |
| Chen, J; Chen, Z; Cui, Q; Geng, B; Meng, Y; Wang, J; Yang, J; Yang, W | 1 |
| Kapsogeorgou, EK; Manoussakis, MN; Polyzos, A; Thanos, D; Vakrakou, AG | 1 |
| Baker, HE; Breyer, MD; Cramer, MS; Harlan, SM; Heinz-Taheny, KM; Heuer, JG; Jaqua, DL; Qi, Z; Shiyanova, TL; Sullivan, JM; Wei, T | 1 |
| Czekuć-Kryskiewicz, E; Karczmarewicz, E; Lorenc, RS | 1 |
| Fu, L; Gao, X; Li, H; Liu, C; Mei, C; Wang, X; Yang, M; Yuan, L | 1 |
| Haniu, H; Matsuda, Y; Murakmi-Murofushi, K; Tsukahara, T | 1 |
| Batatinha, HA; Biondo, LA; Lima, EA; Lira, FS; Rosa Neto, JC; Silveira, LS; Souza, CO; Teixeira, AA | 1 |
| Brenton, J; Cordeiro, MF; Davis, BM; De Groef, L; Guo, L; Malaguarnera, G; Nizari, S; Normando, EM; Pahlitzsch, M; Ravindran, N; Somavarapu, S; Turner, LA | 1 |
| Chen, J; Chen, W; Cheng, Q; Jiang, H; Miao, C; Ren, Y; Sun, Z; Wang, H; Weng, M; Wu, Q; Xu, P; Xu, Y; Zhong, J; Zhu, M | 1 |
| Aiello, LP; Child, A; Folkman, J; Shen, LQ; Weber, GM | 1 |
| Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL | 1 |
| Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A | 1 |
| Bruskina, O; Byrne, RM; Cagliero, E; Crimins, J; Daher, M; Finn, AV; Gold, HK; Hendricks, M; John, MC; Kastrati, A; Nadelson, J; Oh, JS; Palacios, I; Schömig, A | 1 |
| Krentz, A | 1 |
| Divine, G; Habib, ZA; Havstad, SL; Krajenta, R; Lanfear, DE; Pladevall, M; Tang, J; Tzogias, L; Wells, K; Williams, LK | 1 |
| Fanning, EL; Menditto, LA; Weissman, PN | 1 |
| Baader, M; Breitschopf, K; Falk, E; Gerl, M; Kramer, W; Linz, W; Rütten, H; Schäfer, HL; Wohlfart, P | 1 |
| Chan, CF; Crowe, LA; Johnston, DG; Keenan, NG; Pennell, DJ; Varghese, A; Yee, MS | 1 |
| Bassett, K; Carleton, B; Carney, G; Dormuth, CR; Wright, JM | 1 |
| Braga, MF; Leiter, LA | 1 |
| Andresen, BT; Lu, N; Trivedi, H; Whaley-Connell, A | 1 |
| Belinsky, SA; Damiani, LA; Do, KC; Grimes, MJ; Klinge, DM; Lyon, CM; March, TH; Stidley, CA; Thomas, CL | 1 |
| Kieburtz, K | 1 |
| Agrawal, A | 1 |
| Chu, SH; Chun, SH; Li, AH | 1 |
| Georgianos, PI; Lasaridis, AN; Sarafidis, PA; Saratzis, AN; Stafylas, PC | 1 |
| Gipson, DS; Kump, T; Machardy, J; Machardy, N; Pan, C; Peyser, A; Powell, L; Savin, V; Tarapore, F; Trachtman, H; Vento, S | 1 |
| Chandrashekhar, Y; Finn, AV; Narula, J | 1 |
| Cannon, CP; Fitzgerald, PJ; García-García, HM; Gerstein, HC; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Nesto, RW; Ratner, RE; Serruys, PW; van Es, GA | 1 |
| Arora, MK; Balakumar, P; Reddy, K | 1 |
| Dai, B; Fu, L; Hua, Z; Liu, Y; Mei, C; Shen, X; Xiong, X; Zhang, Y | 1 |
| Swanson, A; Watrin, K; Wilder, L | 1 |
| Bandy, D; Bird, NP; Brown, AP; Castiglia, M; Chen, K; Cunningham, VJ; Dixon, IJ; Gold, M; Hallett, WA; Jeter, B; Lai, RY; Lotay, N; Matthews, JC; Matthews, PM; Mistry, P; Nichols, TE; Rabiner, EA; Reiman, EM; Searle, G; Tzimopoulou, S; Whitcher, B; Zvartau-Hind, M | 1 |
| Dhanjil, S; Godsland, IF; Johnston, DG; Pavitt, DV; Richmond, W; Yee, MS | 1 |
| Carboni, E; Carta, AR; Frau, L; Pisanu, A; Spiga, S; Wardas, J | 1 |
| Balkwill, FR; Bossard, M; Candido, JB; Cook, N; Emami-Shahri, N; Hagemann, T; Maniati, E; Nedospasov, SA; Tuveson, DA | 1 |
| Amin, J; Crossno, JT; Joyal, T; Li, H; Nemenoff, RA; Poczobutt, J; Sorenson, AL; Sullivan, T; Weiser-Evans, MC | 1 |
| Bockisch, A; Freudenberg, LS; Jentzen, W; Nagarajah, J; Rosenbaum-Krumme, SJ | 1 |
| Addabbo, F; Montagnani, M; Potenza, MA; Sgarra, L | 1 |
| Gao, W; Jusko, WJ | 1 |
| Kouroumichakis, I; Liakopoulos, V; Maltezos, E; Mikhailidis, DP; Papanas, N; Zarogoulidis, P | 1 |
| Domínguez, RO; González, SE; Marschoff, ER; Repetto, MG; Serra, JA | 1 |
| Brookes, ZL; Huang, L; Nauli, SM; Ong, AC; Prasad, S; Ruff, L; Solanky, T; Upadhyay, VS | 1 |
| Brooks-Worrell, BM; Palmer, JP | 1 |
| Berry, RA; Freed, MI; Greene, DA; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Lachin, JM; Levy, D; Viberti, G; Zinman, B | 1 |
| Haffner, SM | 1 |
| Debiec-Rychter, M; Debrock, G; Oyen, R; Sciot, R; Van Oosterom, A; Vanhentenrijk, V | 1 |
| Kaposzta, Z; Kaski, JC; Markus, HS; Sidhu, JS | 1 |
| Atkinson, RD; Lee, JW; Lytle, C; Straus, DS; Tod, TJ; Vo, KT | 1 |
| Dirani, RG; Freed, MI; Goldstein, BJ; Heise, MA; Kravitz, B; O'neill, MC; Porter, LE; Rosenstock, J; Vinik, AI | 1 |
| Fan, SC; He, CT; Hsieh, CH; Hsing Lee, C; Hung, YJ; Kuo, SW; Lin, SH; Pei, D; Sheu, WH | 1 |
| Das, S; Maji, D; Roy, RU | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC | 1 |
| Eng, C; Farrar, WB; Johnson, MV; Lester, J; Povoski, SP; Suster, S; Walker, MJ; Wen, P; Williams, N; Yee, LD; Young, DC | 1 |
| Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A | 1 |
| Jezior, MR; Langley, RW; Stocker, DJ; Taylor, AJ; Vigersky, RA | 1 |
| Avsar, E; Celikel, C; Emekli, E; Eren, F; Haklar, G; Imeryuz, N; Tahan, V; Tozun, N; Uzun, H; Yavuz, D; Yuksel, M | 1 |
| Goldberg, RA; Lee, S; McCann, JD; Tsirbas, A | 1 |
| Abdel-Latif, A; AlMahameed, A; Bhatt, DL; Blankenship, JC; Brennan, D; Chew, DP; Corbelli, JC; Eres, A; Gilchrist, IC; Grines, C; Hazen, SL; Leesar, M; McErlean, E; Mukherjee, D; Resar, JR; Steinhubl, S; Tan, WA; Tang, HW; Tang, WH; Topol, EJ | 1 |
| Einecke, D | 1 |
| Goldberg, RB | 1 |
| Jacob, S | 1 |
| Arhancet, GB; Blanner, PM; Bolten, CW; Chott, RC; Colca, JR; Ghosh, S; Gulve, EA; Hromockyj, AE; McDonald, WG; Payne, MA; Staten, NR; Sullivan, PM | 1 |
| Cersosimo, E; DeFronzo, RA; Miyazaki, Y; Triplitt, C | 1 |
| Best, JD; Fairley, KF; Farish, S; Kincaid-Smith, P; Proietto, J | 1 |
| Aftring, RP; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Viberti, G; Yu, D; Zinman, B | 1 |
9 review(s) available for rosiglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
[Pathologies of calcium-phosphate homeostasis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Bone and Bones; Calcitriol; Calcium Phosphates; Disease Progression; Fibroblast Growth Factor-23; Homeostasis; Humans; Hyperphosphatemia; Kidney; Parathyroid Glands; Parathyroid Hormone; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Up-Regulation; Vitamin D | 2012 |
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Vascular Diseases | 2009 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.
Topics: Albuminuria; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Proteinuria; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Disease Progression; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Prediabetic State; Rosiglitazone; Thiazolidinediones; Weight Loss | 2010 |
Fibrates: therapeutic potential for diabetic nephropathy?
Topics: Animals; Creatinine; Diabetic Nephropathies; Disease Progression; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; PPAR alpha; Rosiglitazone; Thiazolidinediones | 2012 |
Pre-diabetes, insulin resistance, inflammation and CVD risk.
Topics: Age Factors; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Humans; Inflammation; Insulin Resistance; Prediabetic State; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones | 2003 |
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?
Topics: Adult; Aged; Carotid Arteries; Clinical Trials as Topic; Diabetes Mellitus; Disease Progression; Female; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2007 |
19 trial(s) available for rosiglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Rosiglitazone; Stents; Thiazolidinediones; Vasodilator Agents | 2009 |
Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Imaging, Three-Dimensional; Magnetic Resonance Angiography; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2009 |
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Humans; Hypoglycemic Agents; Infant; Male; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2010 |
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiov
Topics: Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2010 |
A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Disease Progression; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
Topics: Adult; Aged; Autoantibodies; Autoimmunity; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Immunosuppression Therapy; Interferon-gamma; Interleukin-12; Islets of Langerhans; Male; Middle Aged; PPAR gamma; Rosiglitazone; T-Cell Antigen Receptor Specificity; T-Lymphocytes; Thiazolidinediones | 2013 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glyburide; Humans; Hypoglycemic Agents; Metformin; Research Design; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Treatment Outcome | 2002 |
A phase II trial with rosiglitazone in liposarcoma patients.
Topics: Adult; Disease Progression; DNA-Binding Proteins; Female; Fibrinolytic Agents; Gene Expression Regulation, Neoplastic; Humans; Liposarcoma; Male; Microbodies; Middle Aged; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome; Zinc Fingers | 2003 |
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Common; Cohort Studies; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Insulin Resistance; Lipids; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Ultrasonography; Weight Gain | 2004 |
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides | 2006 |
Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Topics: Adiponectin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus; Disease Progression; Female; Glucose Intolerance; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Prevention of type 2 diabetes in the prediabetic population.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Prediabetic State; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima | 2007 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Multivariate Analysis; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media; Vasodilator Agents | 2007 |
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone decreases albuminuria in type 2 diabetic patients.
Topics: Adiponectin; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Linear Models; Middle Aged; Multivariate Analysis; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; PPAR gamma; Proteinuria; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
43 other study(ies) available for rosiglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Rosiglitazone affects the progression of surgically‑induced endometriosis in a rat model.
Topics: Animals; Caspase 3; Disease Models, Animal; Disease Progression; Endometriosis; Female; Gene Expression Regulation; Gynecologic Surgical Procedures; Methionine Adenosyltransferase; PPAR gamma; Rats; Rosiglitazone; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Beige adipocytes contribute to breast cancer progression.
Topics: 3T3-L1 Cells; Adipocytes, Beige; Adipocytes, White; Animals; Breast Neoplasms; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Movement; Culture Media, Conditioned; Disease Progression; Female; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; PPAR gamma; Rosiglitazone; Tumor Microenvironment | 2021 |
FAM3A mediates PPARγ's protection in liver ischemia-reperfusion injury by activating Akt survival pathway and repressing inflammation and oxidative stress.
Topics: Animals; Apoptosis; Cell Survival; Cytokines; Disease Models, Animal; Disease Progression; Gene Expression; Hepatocytes; Liver Diseases; Liver Function Tests; Male; Mice; Mice, Knockout; Oxidative Stress; PPAR gamma; Protein Transport; Proto-Oncogene Proteins c-akt; Reperfusion Injury; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
Impaired anti-inflammatory activity of PPARγ in the salivary epithelia of Sjögren's syndrome patients imposed by intrinsic NF-κB activation.
Topics: Apoptosis; Cell Line; Disease Progression; Epithelium; Gene Expression Profiling; Gene Expression Regulation; Humans; Interleukin-1beta; NF-kappa B; PPAR gamma; Rosiglitazone; Salivary Glands; Signal Transduction; Sjogren's Syndrome; Tissue Array Analysis | 2018 |
Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.
Topics: Animals; Antihypertensive Agents; Creatinine; Dependovirus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Female; Genetic Vectors; Hypertension; Hypoglycemic Agents; Janus Kinases; Lac Operon; Lisinopril; Male; Mice; Nephrectomy; Nitric Oxide Synthase Type III; Renin; Rosiglitazone; Serum Albumin; Severity of Illness Index; Signal Transduction; STAT Transcription Factors | 2018 |
Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Epithelial Cells; Fibrosis; G1 Phase Cell Cycle Checkpoints; Humans; Kidney; Lipids; Male; Phosphorylation; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Renal Agents; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Signal Transduction; Sirolimus | 2018 |
Short-term treatment with a 2-carba analog of cyclic phosphatidic acid induces lowering of plasma cholesterol levels in ApoE-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Carotid Arteries; Cholesterol, LDL; Disease Models, Animal; Disease Progression; Inflammation; Lipid Metabolism; Macrophages; Mice; Mice, Inbred BALB C; Mice, Knockout; Phosphatidic Acids; PPAR gamma; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Triglycerides | 2016 |
Association Between Aerobic Exercise and Rosiglitazone Avoided the NAFLD and Liver Inflammation Exacerbated in PPAR-α Knockout Mice.
Topics: Animals; Body Weight; Disease Progression; Fasting; Inflammation; Lipids; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Organ Size; Phosphorylation; Physical Conditioning, Animal; PPAR alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2017 |
The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Topics: Animals; Antiparkinson Agents; Brain; Cell Survival; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Follow-Up Studies; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rats; Retina; Rosiglitazone; Rotenone; Superior Sagittal Sinus; Thiazolidinediones; Tomography, Optical Coherence | 2016 |
MFHAS1 promotes colorectal cancer progress by regulating polarization of tumor-associated macrophages via STAT6 signaling pathway.
Topics: Adenocarcinoma; Animals; Cell Communication; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Progression; DNA-Binding Proteins; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lectins, C-Type; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Staging; Oncogene Proteins; Phenotype; PPAR gamma; RAW 264.7 Cells; Receptors, Cell Surface; RNA Interference; Rosiglitazone; Signal Transduction; STAT6 Transcription Factor; Thiazolidinediones; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment | 2016 |
Rosiglitazone and delayed onset of proliferative diabetic retinopathy.
Topics: Aged; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Macular Edema; Male; Medical Records; Middle Aged; PPAR gamma; Retrospective Studies; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Visual Acuity | 2008 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2008 |
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Topics: Acute Disease; Cardiovascular Diseases; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2009 |
Clinical practice effect of rosiglitazone discontinuation on glycemic control.
Topics: Adult; Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Compliance; Rosiglitazone; Thiazolidinediones; Withholding Treatment | 2009 |
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzoates; Biomarkers; Cardiotonic Agents; Cell Line; Disease Progression; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Male; Molecular Structure; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; Ramipril; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Survival Rate; Thiazolidinediones | 2009 |
Thiazolidinediones and fractures in men and women.
Topics: Adult; Aged; British Columbia; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk; Rosiglitazone; Sex Factors; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines | 2009 |
Slower decline of renal function after initiation of rosiglitazone in diabetics -- a pilot study.
Topics: Aged; Diabetic Nephropathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Male; Pilot Projects; Renal Insufficiency; Rosiglitazone; Thiazolidinediones; Time Factors | 2009 |
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.
Topics: Adenoma; Animals; Antioxidants; Cell Line, Tumor; Disease Progression; Female; Histone Deacetylases; Humans; Hypoglycemic Agents; Immunohistochemistry; Lung Neoplasms; Mice; Neoplasm Invasiveness; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2009 |
ADAGIO misses a beat?
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Research Design; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2009 |
Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.
Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides | 2009 |
Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.
Topics: Albuminuria; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Macular Edema; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Seeking alternatives to Hard End Points: is imaging the best APPROACH?
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2010 |
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Interactions; Fenofibrate; Kidney; Lipids; Oxidative Stress; PPAR alpha; PPAR gamma; Proteinuria; Rats; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Drug Evaluation, Preclinical; Hypoglycemic Agents; Male; Polycystic Kidney Diseases; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Survival Analysis; Thiazolidinediones; Transforming Growth Factor beta1 | 2010 |
The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
Topics: Adult; Aged; Atherosclerosis; Carotid Artery, Internal; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk; Rosiglitazone; Thiazolidinediones; Ultrasonography | 2010 |
Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Topics: Animals; Disease Models, Animal; Disease Progression; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, ras; Histones; Homeodomain Proteins; I-kappa B Kinase; Inflammation; Mice; Mice, Inbred C57BL; Neoplasm Proteins; NF-kappa B; Pancreatic Diseases; Pancreatic Neoplasms; Phosphorylation; PPAR gamma; Precancerous Conditions; Protein Processing, Post-Translational; Proto-Oncogene Mas; Receptors, Notch; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factor HES-1; Tumor Necrosis Factor-alpha | 2011 |
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
Topics: Adenocarcinoma; Animals; Bone Marrow; Coculture Techniques; Disease Progression; Fluorescent Antibody Technique; Green Fluorescent Proteins; Humans; Hypoglycemic Agents; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Myeloid Cells; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2011 |
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2012 |
Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Random Allocation; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Argentina; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Progression; Female; Geriatric Assessment; Hippocampus; Humans; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Neuropsychological Tests; Oxidative Stress; Pilot Projects; Psychiatric Status Rating Scales; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2012 |
Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.
Topics: Animals; Antioxidants; Arterioles; Calcium; Capillary Permeability; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Genotype; Heterozygote; Hypertension; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myography; Nitric Oxide; Oxidative Stress; Peroxynitrous Acid; Phenotype; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Renal Insufficiency; Reperfusion Injury; Rosiglitazone; Superoxides; Thiazolidinediones; Time Factors; TRPP Cation Channels; Vasodilation; Vasodilator Agents; Venules | 2013 |
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
Topics: Animals; Cytokines; Disease Models, Animal; Disease Progression; Female; Gene Expression Regulation; Hyperplasia; Hypoglycemic Agents; Inflammatory Bowel Diseases; Interleukin-10; Male; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Topics: Animals; Apolipoproteins E; Collagen Type IV; Creatinine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Gemfibrozil; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Mice, Knockout; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Progression; Female; Humans; Hypoglycemic Agents; Ki-67 Antigen; Middle Aged; Pilot Projects; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2007 |
Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunoenzyme Techniques; Insulin; Interleukin-1beta; Interleukin-6; Lipid Peroxidation; Luminescent Measurements; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Thiazolidinedione induced thyroid associated orbitopathy.
Topics: Diplopia; Disease Progression; Drug Therapy, Combination; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Metformin; Middle Aged; Propranolol; Propylthiouracil; Retreatment; Rosiglitazone; Thiazolidinediones | 2007 |
[ADOPT study. Glitazone controls diabetes progression].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
[New rank order of antidiabetic drugs. Using glitazone before sulfonylurea drugs? (interview by Dr. Dirk Einecke)].
Topics: Diabetes Mellitus, Type 2; Disease Progression; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.
Topics: Adiponectin; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Disease Models, Animal; Disease Progression; Heart Rate; Hypertension; Insulin; Lipids; Male; PPAR gamma; Pyridines; Rats; Rats, Inbred Dahl; Rosiglitazone; Sodium Chloride, Dietary; Thiazolidinediones | 2007 |
[ADOPT study: Reevaluation of antidiabetic drugs. Control of diabetes].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
[New prospects for the type 2 diabetic patient. Delaying disease progression].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Prognosis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |